Drug molecules that could target knockdown or knockout of LINC00460 may represent potential therapeutic strategy for overcoming EGFR TKIs resistance and consequently improve the prognosis of EGFR mutant lung cancer patients [118]. This evidence concerns the gene EGFR and lung cancer.